RecruitingNot ApplicableNCT07550790

Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure

Contrast-Induced Acute Kidney Injury in Acute Heart Failure With Renal Dysfunction: The Kidney Protection Strategies Evaluation in Acute Heart Failure (K-PROSE)


Sponsor

Jin Joo Park

Enrollment

190 participants

Start Date

Jul 1, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The K-PROSE study is a randomized clinical investigation evaluating strategies to prevent contrast-induced acute kidney injury (CI-AKI) in patients hospitalized with acute heart failure and moderate renal dysfunction (eGFR 30-75 mL/min/1.73 m²). Patients requiring contrast-enhanced CT imaging are randomized to either standard intravenous saline hydration or a furosemide-based decongestion strategy. Renal function is assessed using serial measurements of creatinine and cystatin C, before and after contrast exposure. By comparing renal outcomes, congestion status, and safety profiles, this study aims to determine whether a decongestion-focused approach provides superior renal protection compared with conventional hydration in high-risk acute heart failure patients.


Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called 0.9 % Normal Saline and a drug called Furosemide for people with heart failure acute and renal dysfunction. The study is currently recruiting participants at 1 location. People eligible for this study include aged 20 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFurosemide

Intravenous furosemide administered to promote diuresis as part of a decongestion-based renal protection strategy.

DRUG0.9 % Normal Saline

Intravenous isotonic saline administered as standard hydration for the prevention of contrast-induced acute kidney injury.


Locations(1)

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07550790


Related Trials